Delta-Fly Pharma, Inc. Share Price

Equities

4598

JP3549370009

Pharmaceuticals

Delayed Japan Exchange 07:00:00 26/04/2024 BST 5-day change 1st Jan Change
778 JPY -2.87% Intraday chart for Delta-Fly Pharma, Inc. -2.02% -23.35%

Financials

Sales 2022 300M 1.9M 152M Sales 2023 - Capitalization 6.56B 41.5M 3.32B
Net income 2022 -967M -6.12M -489M Net income 2023 -1.33B -8.4M -672M EV / Sales 2022 18.9 x
Net cash position 2022 1.27B 8.02M 641M Net cash position 2023 844M 5.34M 427M EV / Sales 2023 -
P/E ratio 2022
-7.17 x
P/E ratio 2023
-4.39 x
Employees 11
Yield 2022 *
-
Yield 2023
-
Free-Float 78.76%
More Fundamentals * Assessed data
Dynamic Chart
Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax CI
Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML CI
Delta-Fly Pharma Inc. Announces Abstracts Submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO Annual Meeting CI
Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323 CI
Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML CI
Delta-Fly Pharma, Inc. announced that it has received ¥503.7238 million in funding from Nippon Chemiphar Co., Ltd. CI
Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited CI
Delta-Fly Pharma, Inc. announced that it expects to receive Ñ1.300842 billion in funding from Macquarie Group Limited CI
Delta-Fly Pharma, Inc. announced that it has received ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm CI
Delta-Fly Pharma, Inc. announced that it expects to receive ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm CI
Delta-Fly Pharma Enters into Licensing Agreement with Nippon Chemifa CI
Delta-Fly Pharma, Inc. Initiates Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927 CI
Certain Common Shares of Delta-Fly Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-JAN-2019. CI
Delta-Fly Pharma, Inc. has completed an IPO in the amount of ¥3.339 billion. CI
Delta-Fly Pharma, Inc. has filed an IPO. CI
More news
1 day-2.87%
1 week-2.02%
Current month-7.60%
1 month-6.27%
3 months-13.36%
6 months-35.22%
Current year-23.35%
More quotes
1 week
772.00
Extreme 772
819.00
1 month
772.00
Extreme 772
856.00
Current year
762.00
Extreme 762
1 078.00
1 year
762.00
Extreme 762
1 825.00
3 years
749.00
Extreme 749
2 085.00
5 years
688.00
Extreme 688
2 865.00
10 years
688.00
Extreme 688
5 380.00
More quotes
Managers TitleAgeSince
Founder 74 05/12/10
Chief Administrative Officer 58 31/08/19
Chief Tech/Sci/R&D Officer 61 31/03/12
Members of the board TitleAgeSince
Founder 74 05/12/10
Chief Tech/Sci/R&D Officer 61 31/03/12
Director/Board Member 63 31/07/16
More insiders
Date Price Change Volume
26/04/24 778 -2.87% 292,300
25/04/24 801 -0.99% 61,800
24/04/24 809 -0.37% 56,000
23/04/24 812 +0.87% 67,900
22/04/24 805 +1.39% 50,300

Delayed Quote Japan Exchange, April 26, 2024 at 07:00 am

More quotes
Delta-Fly Pharma, Inc. is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.
Calendar
More about the company